Contents

Preface ............................................................................................................................... v
Contributors ................................................................................................................... ix

1 An Overview of Adjuvant Use ..................................................................................... 1
   Robert Edelman
2 Harmful and Beneficial Activities of Immunological Adjuvants ......................... 29
   Duncan E. S. Stewart-Tull
3 Freund’s Adjuvants ................................................................................................. 49
   Erik B. Lindblad
4 Aluminum Compounds as Vaccine Adjuvants ......................................................... 65
   Rajesh K. Gupta and Bradford E. Rost
5 Poly(Lactide-Coglycolide) Microparticles As Vaccine Adjuvants ....................... 91
   Derek T. O’Hagan and Manmohan Singh
6 Poly(Methyl Methacrylate) Nanoparticles as Vaccine Adjuvants ....................... 105
   Jörg Kreuter
7 Aqueous Formulation of Adjuvant-Active Nonionic Block Copolymers ............... 121
   Charles W. Todd and Mark J. Newman
8 Liposomes As Immunological Adjuvants and Vaccine Carriers ......................... 137
   Gregory Gregoriadis, Brenda McCormack, Mia Obrenovic, Yvonne Perrie, and Roghieh Saffie
9 Immunopotentiating Reconstituted Influenza Virosomes (IRIVs) ......................... 151
   Reinhard Glück
10 Cochleates for Induction of Mucosal and Systemic Immune Responses .............. 179
   Susan Gould-Fogerite and Raphael J. Mannino
11 Virus-like Particles As Vaccine Adjuvants ............................................................... 197
   Sarah C. Gilbert
12 The Adjuvant MF59: A 10-Year Perspective .......................................................... 211
   Gary Ott, Ramachandran Radhakrishnan, Jia-Hwa Fang, and Maninder Hora
Contents

13 Preparation of the Syntex Adjuvant Formulation (SAF, SAF-m, and SAF-1) .............................................................. 229
Deborah M. Lidgate

14 The ISCOM™ Technology ................................................................. 239
Karin Lövgren-Bengtsson and Bror Morein

15 QS-21 Adjuvant ............................................................................ 259
Charlotte Read Kensil

16 MPL® Immunostimulant: Adjuvant Formulations ....................... 273
J. Terry Ulrich

17 Cytokines As Vaccine Adjuvants: The Use of Interleukin-2 .......... 283
Martin A. Giedlin

18 DNA As an Adjuvant ................................................................... 299
David C. Neujahr and David S. Pisetsky

19 Transcutaneous Immunization ......................................................... 315
Gregory M. Glenn, Tanya Scharton-Kersten, and Russell Vassell

20 Mutant Heat-Labile Entertoxins As Adjuvants for CTL Induction.... 327
Jason A. Neidleman, Gary Ott, and Derek O’Hagan

Index ............................................................................................................ 337
Vaccine Adjuvants
Preparation Methods and Research Protocols
O'Hagan, D.T. (Ed.)
2000, X, 342 p., Hardcover
A product of Humana Press